Steroid-Sparing Strategies: Long-Acting Inhaled β2-Agonists

Overcoming Steroid Insensitivity in Respiratory Disease

Volumn , Issue , 2008, Pages 163-185

  Miller Larsson, Anna ^a   Selroos, Olof ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b Selroos Medical Consulting   (Sweden)

Author keywords

Budesonide formoterol (BUD FORM); Chronic obstructive pulmonary disease (COPD); Hypothalamic pituitary adrenal (HPA) axis; Long acting inhaled 2 agonists (LABA); Salmeterol fluticasone (SALM FP)

Indexed keywords

EID: 58349120261     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470985731.ch10     Document Type: Chapter

References (121)

1. Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandström T, Jorup C, Welte T. Adjustable maintenance dosing with budesonide/formoterol improves asthma control compared with fi xeddose salmeterol/fl uticasone. Curr Med Res Opin 2004; 20: 225-240.
2. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-?B and lack of I-?B involvement. Br J Pharmacol 1999; 127: 1003-10011.
3. Adcock IM, Yanagawa H, Hewitt AH, Buck H. Effects of long-acting ß-agonists and glucocorticoids on cytokine expression. Am J Respir Crit Care Med 2003; 167: A356.
4. Akabane H, Murata M, Kufota M, Takashima E, Tanaka H, Inagaki N, Horifa M, Nagai H. Effects of salmeterol xinafoate and fl uticasone propionate on immunological activation of human cultured mast cells. Allergol Int 2006; 55: 387-393.
5. Ammit AJ, Lazaar AL, Irani C, O'Neill GM et al. Tumor necrosis factor-a-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 2002; 26: 465-474.
6. Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting ß2-agonists: improved clinical effi cacy and dosing options in patients with asthma. J Asthma 2005; 42: 715-724.
7. Baouz S, Giron-Michel J, Azzarone B, Giuliani M et al. Lung myofi broblasts as targets of salmeterol and fl uticasone propionate: inhibition of a-SMA and NF-?B. Int Immunol 2005; 17: 1473-1481.
8. Baraniuk J, Murray JJ, Nathan RA, Berger WE et al. Fluticasone alone or in combination with salmeterol versus triamcinolone in asthma. Chest 1999; 116: 625-632.
9. Barnes PJ. Corticosteroid resistance in airway disease Proc Am Thorac Soc 2004; 1: 264-268.
10. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in infl ammatory lung diseases. Eur Respir J 2005; 25: 552-563.
11. Barnes PJ, Pedersen S, Busse WW. Effi cacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S53.
12. Bateman ED, Bantje TA, Joao Gomes M, Toumbis M, Huber R, Naya I, Eliraz A. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fl uticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2003; 2: 275-281.
13. Bellettato C, Adcock IM, Ito K, Caramori G et al. Rhinovirus infection reduces glucocorticoid receptor nuclear translocation in airway epithelial cells. Am J Respir Crit Care Med 2003; 167: A578.
14. Bisgaard H, LeRoux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130: 1733-1743.
15. Bloom J, Calhoun W, Koenig S, Yancey S et al. Fluticasone propionate/salmeterol 100/50 mcg is inhaled steroid sparing in patients who require fl uticasone propionate 250 mcg for asthma stability. Am J Respir Crit Care Med 2003; 167: A891.
16. Buhl R. Budesonide/formoterol for the treatment of asthma. Expert Opin Pharmacother 2003; 4: 1393-1406.
17. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Brüggenjürgen B, Willich SN, Vogelmeier C. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fi xed dosing. Curr Med Res Opin 2004; 20: 1209-1220.
18. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adults with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463.
19. Busse W, Koenig SM, Oppenheimer J, Sahn SA et al. Steroid-sparing effects of fl uticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fl uticasone propionate 250 μg administered twice daily. J Allergy Clin Immunol 2003; 111: 57-65.
20. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
21. Canonica GW, Castellani P, Cazzola M, Fabbri LM et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fi xed maintenance dosing. Pulm Pharmacol Ther 2004; 17: 239-247.
22. Clark AR, Lasa M. Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. Curr Opin Pharmacol 2003; 3: 404-411.
23. Contoli M, Message SD, Laza-Stanca V, Edwards MR et al. Role of defi cient type III interferonlambda production in asthma exacerbations. Nat Med 2006; 12: 1023-1026.
24. Edwards MR, Johnson MW, Johnston SL. Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol 2006; 34: 616-624.
25. Eickelberg O, Roth M, Lörx R, Bruce V, Rüdiger J, Johnson M, Block LH. Ligand-independent activation of the glucocorticoid receptor by ß2-adrenergic receptor agonists in primary human lung fi broblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010.
26. Ellul-Micallef R, Johansson SÅ. Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Brit J Clin Pharmacol 1983; 15: 419-422.
27. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J, Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004a; 59: 550-556.
28. FitzGerald JM, Olsson P, Michils A. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler-effi cacy and safety. Int J Clin Pract 2004b; 58: 18-25.
29. FitzGerald JM, Sears MR, Boulet L-P, Becker AB et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fi xed dosing: a fi ve-month multicentre Canadian study. Can Respir J 2003; 10: 427-434.
30. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117: 400-406.
31. Fragaki K, Kileztky C, Trentesaux C, Zahm JM, Bajolet O, Johnson M, Puchelle E. Downregulation by a long-acting ß2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial infl ammatory mediator production. Am J Physiol Lung Cell Mol Physiol 2006; 291: L11-18.
32. Gibson PG. Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur Respir J 2005; 25: 397-399.
33. Gibson PG, Powell H, Ducharme F. Long-acting beta2-agonists as an inhaled corticosteroidsparing agent for chronic asthma in adults and children. Cochrane Database Systematic Review 2005; 4: CD005076.
34. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Publication no. NIH-NHLI 02-3569. Bethesda, MD: National Institutes of Health 2002.
35. Green RH, Brightling CE, McKenna S, Hargadon B et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway infl ammation and responsiveness. Eur Respir J 2006; 27: 1144-1151.
36. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled steroid. Lancet 1994; 344: 219-224.
37. Greiff L, Andersson M, Svensson C, Akerlund A, Alkner U, Persson CG. Effects of two weeks of topical budesonide treatment on microvascular exudative responsiveness in healthy human nasal airways. Eur Respir J 1997; 10: 841-845.
38. Greiff L, Wollmer P, Andersson M, Svensson C, Persson CGA. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax 1998; 53, 1010-1013.
39. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-275.
40. Haque RA, Johnson M, Adcock IM, Barnes PJ. Addition of salmeterol to fl uticasone prolongs retention of glucocorticoid receptors within the nucleus of BEAS-2B cells and enhances downstream glucocorticoid effects. Proc Am Thorac Soc 2006; 3: A78.
41. Hew M, Bhavsar P, Torrego A, Meah S et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006; 174: 134-141.
42. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fl uticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003; 97: 555-562.
43. Ind PW, Haughney J, Price D, Rosen J-P, Kennelly J. Adjustable and fi xed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004; 98: 464-475.
44. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-?B suppression. J Exp Med 2006; 203: 7-13.
45. Jarjour NN, Wilson SJ, Koenig SM, Laviolette M et al. Control of airway infl ammation maintained at a lower steroid dose with 100/50 μg of fl uticasone propionate/salmeterol. J Allergy Clin Immunol 2006; 118: 44-52.
46. Jazrawi E, Ito K, Barnes PJ, Adcock IM. Effect of budesonide and formoterol on glucocorticoid receptor DNA binding and transactivation in BEAS-2B cells Proc Am Thorac Soc 2005; 2: A108.
47. Jeffery PK, Venge P, Gizycki MJ, Egerod I, Dahl R, Faurschou P. Effects of salmeterol on mucosal infl ammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20: 1378-1385.
48. Jendbro M, Johansson CJ, Strandberg P, Falk-Nilsson H, Edsbäcker S. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001; 29: 769-776.
49. Jenkins C, Woolcock AJ, Saarelainen P, Lundbäck B, James MH. Salmeterol/fl uticasone propionate combination therapy 50/250 μg bid is more effective than budesonide 800 μg bid in treating moderate-to-severe asthma. Respir Med 2000; 94: 715-723.
50. Johansson G, McIvor RA, Purello D'Ambrosio F, Gratziou C, James MH. Comparison of salmeterol/ fl uticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin Drug Invest 2001; 21: 633-642.
51. Kaur M, Chivers JE, Giembycz MA, Newton R. Long-acting ß2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airways epithelial and smooth muscle cells. Mol Pharmacol 2007; [Epub ahead of print]
52. Kips JC, O'Connor J, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinfl ammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
53. Koopmans JG, Lutter R, Jansen HM, van der Zee JS. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial infl ammation in asthma. Thorax 2006; 61: 306-312.
54. Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001; 17: 1070-1077.
55. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson NC. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123: 1480-1487.
56. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. J Amer Med Assoc 2001; 285: 2594-2603.
57. Leufgen H, Rüdiger JJ, Herrmann MJ, Meyer L et al. Glucocorticoid receptor activation by steroids and long-acting ß2-agonists in vivo: A double-blind crossover study. Am J Respir Crit Care Med 2002; 165: A618.
58. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003; 111: 3-22.
59. Leuppi JD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, Tamm M. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fi xed dosing. Swiss Med Wkly 2003; 133: 302-309.
60. Li X, Ward C, Thien F, Bish R et al. An antiinfl ammatory effect of salmeterol, a long-acting ß2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-1499.
61. Lipworth BJ, Jackson M. Safety of inhaled and intranasal corticosteroids. Lessons for the new millennium. Drug Safety 2000; 23: 11-33.
62. Lovén J, Svitacheva N, Jerre A, Miller-Larsson A, Korn SH. Anti-infl ammatory activity of ß2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor. Eur Respir J 2007; 30: 848-856.
63. Maneechotesuwan K, Essilfie-Quaye S, Meah S, Kelly C, Kharitonov SA, Adcock IM, Barnes PJ. Formoterol attenuates neutrophilic airway infl ammation in asthma. Chest 2005; 128: 1936-1942.
64. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004; 113: 1100-1108.
65. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway infl ammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-930.
66. Mercado N, To Y, Ito M, Adcock IM, Barnes PJ, Ito K. Two novel phenotypes in severe asthma may require distinct treatments. Proc Am Thorac Soc 2006; 3: A16.
67. Michils A, Peché R, Verbraeken J, Vandenhoven G, Wollaert L, Duquenne V. SURF Study: reallife effectiveness of budesonide/formoterol (B/F) adjustable maintenance dosing. Allergy Clin Immunol Int 2003; 15: 56, [Abstract P-2-39].
68. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 623-630
69. Myo S, Zhu X, Myou S, Meliton AY et al. Additive blockade of ß2-integrin adhesion of eosinophils by salmeterol and fl uticasone propionate. Eur Respir J 2004; 23: 511-517.
70. Nie M, Knox AJ, Pang L. ß2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 2005; 175: 478-86.
71. Nielsen LP, Pedersen B, Faurschou P, Madsen F, Wilcke JTR, Dahl R. Salmeterol reduces the need for inhaled corticosteroids in steroid-dependent asthmatics. Respir Med 1999; 93: 863-868.
72. Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med 1998; 157: 184-191.
73. Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 2004; 3: 27-41.
74. O'Byrne PM, Barnes PJ, Rodriguez-Rousin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield AE. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
75. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
76. Oddera S, Silvestri M, Testi R, Rossi GA. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 1998; 65: 199-204.
77. Orsida BE, Ward C, Li X, Bish R, Wilson JW, Thien F, Walters EH. Effect of a long-acting ß2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164: 117-121.
78. Overbeek SE, Mulder PG, Baelemans SM, Hoogsteden HC, Prins JB. Formoterol added to lowdose budesonide has no additional antiinfl ammatory effect in asthmatic patients. Chest 2005; 128: 1121-1127.
79. Pace E, Gagliardo R, Melis M, La Grutta S et al. Synergistic effects of fl uticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol 2004; 114: 1216-1223.
80. Paggiaro PL, Dente FL, Morelli MC, Bancalari L et al. Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. Am J Respir Crit Care Med 1994; 149: 1447-1451.
81. Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative effi cacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244-249.
82. Pang L, Knox AJ. Synergistic inhibition by ß2-agonists and corticosteroids on tumor necrosis factor-a-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000; 23: 79-85.
83. Pang L, Knox AJ. Regulation of TNF-a-induced eotaxin release from cultured human airway smooth muscle cells by ß2-agonists and corticosteroids. FASEB J 2001; 15: 261-269.
84. Parameswaran K, Inman MD, Watson RM, Morris MM et al. Protective effects of fl uticasone on allergen-induced airway responses and sputum infl ammatory markers. Can Respir J 2000; 7: 313-319.
85. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne PM, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
86. Persdotter S, Lindahl M, Malm-Erjefält M, von Wachenfeldt, Korn SH, Stevens T, Miller-Larsson A. Cooperative effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium. Intern Arch Allergy Immunol 2007; 143: 201-210.
87. Profita M, Gagliardo R, Di Giorgi R, Pompeo F et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 2005; 60: 323-329.
88. Rabe KF, Pizzichini E, Ställberg B, Romero S et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double-blind trial. Chest 2006; 129: 246-256.
89. Reid DW, Ward C, Wang N, Zheng L, Bish R, Orsida B, Walters EH. Possible anti-infl ammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003; 21: 994-999.
90. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med 1998; 92: 1017-1021.
91. Roth M, Johnson PRA, Rüdiger JJ, King GG et al. Interaction between glucocorticoids and ß2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-1299.
92. Scicchitano R, Aalbers R, Ukena D, Manjra A et al. Effi cacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418.
93. Seberová E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000; 94: 607-611.
94. Self T, Rumbak MJ, Kelso T, Eberle L et al. Does salmeterol facilitate "step-down" therapy in patients with asthma receiving moderate to high doses of inhaled corticosteroids? Curr Ther Res 1998; 59: 803-811.
95. Silvestri M, Fregonese L, Sabatini F, Dasic G, Rossi GA. Fluticasone and salmeterol downregulate in vitro, fi broblast proliferation and ICAM-1 or H-CAM expression. Eur Respir J 2001; 18: 139-145.
96. Sin DD, Man J, Sharpe H, Gan WQ, Man SFP. Pharmacological management to reduce exacerbations in adults with asthma: A systematic review and meta-analysis. J Am Med Assoc 2004; 292: 367-376.
97. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Additive anti-infl ammatory effect of formoterol and budesonide on human lung fi broblasts. Thorax 2002; 57: 237-241.
98. Ställberg B, Olsson P, Jörgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fi xed dosing. Int J Clin Pract 2003; 57: 656-661.
99. Subbarao P, Dorman SC, Rerecich T, Watson RM, Gauvreau GM, O'Byrne PM. Protection by budesonide and fl uticasone on allergen-induced airway responses after discontinuation of therapy. J Allergy Clin Immunol 2005; 115: 745-750.
100. Szafranski W, Cukier A, Ramirez A, Menga G et al. Effi cacy and safety of budesonide/formoterol in the management of obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
101. Tattersfield AE, Postma DS, Barnes PJ, Svensson K et al. Exacerbations of asthma. A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160: 594-599.
102. Tintinger GR, Anderson R, Theron AJ, Ramafi G, Ker JA. Comparison of the effects of selective and non-selective beta-adrenoreceptor agonists on the pro-infl ammatory activities of human neutrophils in vitro. Infl ammation 2000; 24: 239-249.
103. To Y, Ito M, Adcock IM, Barnes PJ, Ito K. Formoterol restores corticosteroid responses in corticosteroid-insensitive asthma. Eur Respir J 2005a; 26: 50s
104. To Y, Adcock IM, Barnes PJ, Ito K. Salmeterol treatment improves corticosteroid responsiveness in patients with corticosteroid-insensitive severe asthma Eur Respir J 2005b; 26: 465s.
105. Todorova L, Gürcan E, Miller-Larsson A, Westergren-Thorsson G. Lung fi broblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. Am J Respir Cell Mol Biol 2006; 34: 92-100.
106. Todorova L, Bjermer L, Miller-Larsson A, Westergren-Thorsson G. Inhibitory effects of fudesonide and formoterol in combination on TGFß-induced proteoglycan production by bronchial biopsy fi broblasts from healthy and mild asthmatic subjects. Eur Respir J 2007; 30: 352
107. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982; 70: 288-298.
108. Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta2adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
109. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM. Glucocorticoid receptor nuclear translocation in airway cells after inhaledcombination therapy. Am J Respir Crit Care Med 2005; 172: 704-712.
110. Vanacker NJ, Palmans E, Pauwels RA, Kips JC. Effect of combining salmeterol and fl uticasone on the progression of airway remodeling. Am J Respir Crit Care Med 2002; 166: 1128-1134.
111. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-828.
112. Volonaki E, Psarras S, Xepapadaki P, Psomali D, Gourgiotis D, Papadopoulos NG. Synergistic effects of fl uticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors. Clin Exp Allergy 2006; 36: 1268-1273.
113. Wales D, Makker H, Kane J, McDowell P, O'Driscoll BR. Systemic bioavailability and potency of high-dose inhaled corticosteroids. A comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 1999; 115: 1278-1284.
114. Wallin A, Sandström T, Cioppa GD, Holgate S, Wilson S. The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. Respir Med 2002; 96: 1021-1025.
115. Wallin A, Sandström T, Söderberg M, Howarth P et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal infl ammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159: 79-86.
116. Wallin A, Sue-Chu M, Bjermer L, Ward J et al. Effect of inhaled fl uticasone with and without salmeterol on airway infl ammation in asthma. J Allergy Clin Immunol 2003; 112: 72-78.
117. Wark PA, Johnston SL, Bucchieri F, Powell R et al. Asthmatic bronchial epithelial cells have a defi cient innate immune response to infection with rhinovirus. J Exp Med 2005; 201: 937-947.
118. Wilding P, Clark M, Thompson Coon J, Lewis S et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314: 1441-1446.
119. Wilson SJ, Wallin A, Della-Cioppa G, Sandstrom T, Holgate ST. Effects of budesonide and formoterol on NF-?B, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164: 1047-1052.
120. Woolcock A, Lundback B, Ringdal, Jacques LA. Comparison of the addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
121. Yanagawa H, Ito K, Barnes PJ, Adcock IM. Formoterol-induced glucocorticoid receptor nuclear translocation in monocytes and U937 cells but not epithelial cell lines. Am J Respir Crit Care Med 2001; 163: A734.